
发表一篇学和医学成像类SCI论文
需要多少钱?
Abstract:
Real-world data on regimens for relapsed/refractory multiple myeloma (RRMM) represent an important component of therapeutic decision-making. This multi-centric, retrospective, observational study conducted by the treating physicians evaluated the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in 155 patients who received ixazomib via early access programs in Greece, the UK, and the Czech Republic. Median age was 68 years; 17% had an Eastern Cooperative Oncology Group performance status ≥ 2; median number of prior therapies was 1 (range 1–7); 91%, 47%, and 17% had received prior bortezomib, thalidomide, and lenalidomide, respectively. Median duration of exposure to ixazomib was 9.6 months. Overall response rate was 74%, including 35% very good partial response or better (16% complete response). Median progression-free survival (PFS) was 27.6 months (27.6 and 19.9 months in patients with 1 or > 1 prior lines, respectively). IRd treatment for ≥ 6 months was associated with longer PFS (hazard ratio 0.06). Fourteen patients (9%) discontinued IRd due to adverse events/toxicity in the absence of disease progression. Peripheral neuropathy was reported in 35% of patients (3% grades 3–4). These findings support the results of the phase III TOURMALINE-MM1 trial in a broader real-world RRMM population.
展开更多
最新影响因子:4.03 | 期刊ISSN:0939-5555 | CiteScore:1.82 |
出版周期:Monthly | 是否OA:YES | 出版年份:1991 |
自引率:5.00% | 研究方向:医学-血液学 |
出版地区:GERMANY |
SCI期刊coverage:Science Citation Index Expanded(科学引文索引扩展)
专业编辑在线一对一答疑及时解决您的问题
Annals of Hematology covers the whole spectrum of clinical and experimental hematology, hemostaseology, blood transfusion, and related aspects of medical oncology, including diagnosis and treatment of leukemias, lymphatic neoplasias and solid tumors, and transplantation of hematopoietic stem cells. Coverage includes general aspects of oncology, molecular biology and immunology as pertinent to problems of human blood disease. The journal is associated with the German Society for Hematology and Medical Oncology, and the Austrian Society for Hematology and Oncology. The Editor-in-Chief is Arnold Ganser, Department of Hematology, Hemostasis and Oncology, Medizinische Hochschule Hannover.
《血液学年鉴》涵盖了临床和实验血液学、止血学、输血以及肿瘤医学的相关领域,包括白血病、淋巴肿瘤和实体肿瘤的诊断和治疗,以及造血干细胞的移植。内容包括与人类血液病相关的肿瘤学、分子生物学和免疫学的一般方面。该杂志与德国血液学和医学肿瘤学协会,以及奥地利血液学和肿瘤学协会有联系。 主编:阿诺德·甘瑟,德国汉诺威大学血液、止血和肿瘤学系。
大类(学科) | 小类(学科) | 学科排名 |
医学 |
HEMATOLOGY (血液学) 3区 |
28/71 |
年度总发文量 | 年度论文发表量 | 年度综述发表量 |
201 | 180 | 21 |
引文计数(2018)
文献(2015-2017)
1861次引用
1023篇文献
序号 | 类别 | 排名 | 百分位 |
1 |
大类(学科):Medicine
小类(学科):Hematology
|
#51/120
点击查看排名表
|
|
推荐刊物均可到国家新闻出
版总署网站查询正刊
可签署保密协议 ,不透露任
何用户信息可跟踪进程,全程
协议
1对1服务,7x24小时在线
14年经验沉淀,实体公司
运营
liting7111
liting7111
研究方向:NHL
接受率: 中等(50%命中)
liting7111
研究方向:医学 血液学
审稿时间: 3个月内
liting7111
研究方向:hematology
审稿时间: 3个月内 接受率: 非常困难(几乎不命中)
liting7111
研究方向:移植排斥
审稿时间: 2个月内 接受率: 中等(50%命中)
liting7111
接受率: 中等(50%命中)
影响因子:2.293
ISSN:0962-7286
研究方向:农林科学-动物学
影响因子:1.083
ISSN:0932-0814
研究方向:农林科学-动物学
影响因子:0.65
ISSN:0008-1078
研究方向:农林科学-动物学
影响因子:0.8
ISSN:0046-9939
研究方向:FISHERIES-ZOOLOGY
影响因子:0.913
ISSN:0137-1592
研究方向:FISHERIES-ZOOLOGY
影响因子:3.605
ISSN:0145-305X
研究方向:医学-动物学
影响因子:1.565
ISSN:1532-0820
研究方向:医学-动物学
影响因子:0.362
ISSN:0324-0770
研究方向:ZOOLOGY-
影响因子:0.653
ISSN:1525-2647
研究方向:医学-动物学
专注医学期刊服务14年
我是360期刊网在线指导老师,请问您想咨询什么等级的期刊(省级、国家级、核心、SCI)?我们提供以下服务:
1.医学期刊推荐
2.医学SCI科研服务
3.医生论文咨询
现在咨询抢期刊推荐直到录用,再付款名额
客服正在输入...
ANNALS OF HEMATOLOGY 投稿经验
(由下方点评分析获得,6人参与,16841人阅读)